title: Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab.
authors.affiliation: S.C. Oncologia, Azienda Ospedaliera, Perugia, Italy. mariantonietta.colozza@tin.it
authors.forename: Mariantonietta
authors.initials: M
authors.lastname: Colozza
authors.forename: Elisa
authors.initials: E
authors.lastname: Minenza
authors.forename: Stefania
authors.initials: S
authors.lastname: Gori
authors.forename: Daniela
authors.initials: D
authors.lastname: Fenocchio
authors.forename: Cristina
authors.initials: C
authors.lastname: Paolucci
authors.forename: Cynthia
authors.initials: C
authors.lastname: Aristei
authors.forename: Piero
authors.initials: P
authors.lastname: Floridi
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D011859:Radiography; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human